Hibercell, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding

Established: 2019-01-01

Employees: 51

Market Cap: -

Website: http://www.hibercell.com

Clinical Trials

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: NSCLC

Interventions: Biological: Imprime PGG Injection
Biological: Cetuximab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-04-03

Last Posted Date: 2016-11-29

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 90

Registration Number: NCT00874848

Locations: 🇺🇸
Allison Cancer Center, Midland, Texas, United States
🇩🇪
Municipal Clinic Frankfurt Hoescht, Frankfurt, Germany
🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States

and more 11 locations

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Imprime PGG® Injection
Biological: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-04-02

Last Posted Date: 2017-03-03

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 90

Registration Number: NCT00874107

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
University of Texas Health Science Center, San Antonio, San Antonio, Texas, United States

and more 7 locations

Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma

Phase 1

Completed

Conditions: Recurrent Colorectal Carcinoma
Progressive Colorectal Carcinoma

Interventions: Biological: Safety and efficacy of escalating doses
Biological: Safety and efficacy of escalating doses.

First Posted Date: 2007-10-17

Last Posted Date: 2010-03-31

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 48

Registration Number: NCT00545545

Locations: 🇵🇭
Medical City, Makati City, Philippines
🇵🇭
Philippine General Hospital, Manila, Philippines

Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Imprime PGG TM for Injection

First Posted Date: 2007-10-11

Last Posted Date: 2007-10-11

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 66

Registration Number: NCT00542529

Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Imprime PGG TM for Injection

First Posted Date: 2007-10-11

Last Posted Date: 2007-10-11

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 12

Registration Number: NCT00542464

Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Imprime PGG

First Posted Date: 2007-10-11

Last Posted Date: 2007-10-11

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 24

Registration Number: NCT00542217

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy